These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 30794891

  • 1. Tumor PD-L1 expression in malignant pleural and peritoneal mesothelioma by Dako PD-L1 22C3 pharmDx and Dako PD-L1 28-8 pharmDx assays.
    Chapel DB, Stewart R, Furtado LV, Husain AN, Krausz T, Deftereos G.
    Hum Pathol; 2019 May; 87():11-17. PubMed ID: 30794891
    [Abstract] [Full Text] [Related]

  • 2. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 3. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
    Ahn S, Kim KM.
    Mod Pathol; 2021 Sep 01; 34(9):1719-1727. PubMed ID: 34002009
    [Abstract] [Full Text] [Related]

  • 4. Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients.
    Ilie M, Juco J, Huang L, Hofman V, Khambata-Ford S, Hofman P.
    Cancer Cytopathol; 2018 Apr 01; 126(4):264-274. PubMed ID: 29411536
    [Abstract] [Full Text] [Related]

  • 5. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A, Barberis M, Franco R, De Luca G, Pace MV, Staibano S, Volante M, Buttitta F, Guerini-Rocco E, Righi L, D'antuono T, Scagliotti GV, Pinto C, De Rosa G, Papotti M.
    J Thorac Oncol; 2017 Nov 01; 12(11):1654-1663. PubMed ID: 28818609
    [Abstract] [Full Text] [Related]

  • 6. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 Nov 01; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 7. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep 01; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 8. Expression of PD-L1 in Patients With Malignant Peritoneal Mesothelioma: A Pilot Study.
    Gazivoda VP, Kangas-Dick AW, Greenbaum AA, Roshal J, Chen C, Moore DF, Langan RC, Kennedy TJ, Minerowicz C, Alexander HR.
    J Surg Res; 2022 Sep 01; 277():131-137. PubMed ID: 35489218
    [Abstract] [Full Text] [Related]

  • 9. Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma.
    Metaxas Y, Rivalland G, Mauti LA, Klingbiel D, Kao S, Schmid S, Nowak AK, Gautschi O, Bartnick T, Hughes BG, Bouchaab H, Rothschild SI, Pavlakis N, Wolleb S, Petrausch U, O'Byrne K, Froesch P, Löffler-Baumann M, Pratsch-Peter S, Russell P, Mingrone W, Savic S, Thapa B, Früh M, Pless M, von Moos R, John T.
    J Thorac Oncol; 2018 Nov 01; 13(11):1784-1791. PubMed ID: 30142389
    [Abstract] [Full Text] [Related]

  • 10. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
    Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, Tomii K.
    Anticancer Res; 2018 Dec 01; 38(12):6891-6895. PubMed ID: 30504406
    [Abstract] [Full Text] [Related]

  • 11. Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms.
    Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, Hofman P.
    PLoS One; 2017 Dec 01; 12(8):e0183023. PubMed ID: 28797130
    [Abstract] [Full Text] [Related]

  • 12. Development of a Companion Diagnostic PD-L1 Immunohistochemistry Assay for Pembrolizumab Therapy in Non-Small-cell Lung Cancer.
    Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Ponto G, Dolled-Filhart M, Emancipator K, Stanforth D, Kulangara K.
    Appl Immunohistochem Mol Morphol; 2016 Jul 01; 24(6):392-7. PubMed ID: 27333219
    [Abstract] [Full Text] [Related]

  • 13. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Pardo-Aranda N, Navarro-Mendivil A, Martinez-Marti A, Zugazagoitia J, Sansano I, Montoro MA, Enguita A, Felip E.
    Lung Cancer; 2016 Jun 01; 96():1-6. PubMed ID: 27133741
    [Abstract] [Full Text] [Related]

  • 14. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun 01; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 15. Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma.
    Kao SC, Cheng YY, Williams M, Kirschner MB, Madore J, Lum T, Sarun KH, Linton A, McCaughan B, Klebe S, van Zandwijk N, Scolyer RA, Boyer MJ, Cooper WA, Reid G.
    J Thorac Oncol; 2017 Sep 01; 12(9):1421-1433. PubMed ID: 28629895
    [Abstract] [Full Text] [Related]

  • 16. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
    Dabbagh TZ, Sughayer MA.
    Appl Immunohistochem Mol Morphol; 2021 Jul 01; 29(6):462-466. PubMed ID: 33480602
    [Abstract] [Full Text] [Related]

  • 17. A real-world, comparative study of FDA-approved diagnostic assays PD-L1 IHC 28-8 and 22C3 in lung cancer and other malignancies.
    Batenchuk C, Albitar M, Zerba K, Sudarsanam S, Chizhevsky V, Jin C, Burns V.
    J Clin Pathol; 2018 Dec 01; 71(12):1078-1083. PubMed ID: 30275099
    [Abstract] [Full Text] [Related]

  • 18. Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement.
    Bronte G, Delmonte A, Burgio MA, Verlicchi A, Puccetti M, Bravaccini S, Cravero P, Tumedei MM, Diano D, Rossi G, Ulivi P, Martinelli G, Crinò L.
    Lung Cancer; 2020 Apr 01; 142():47-50. PubMed ID: 32088605
    [Abstract] [Full Text] [Related]

  • 19. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct 01; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 20. Comparison of PD-L1 Expression Using 2 Validated PD-L1 IHC 22C3 pharmDx Methods in Non-Small Cell Lung Cancer in a Routine Hospital Setting.
    Skov BG.
    Appl Immunohistochem Mol Morphol; 2021 Jan 01; 29(1):49-55. PubMed ID: 31913160
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.